Abstract
Despite over 50 yr of experience with steroid replacement therapy the management of congenital adrenal hyperplasia (CAH) remains difficult and clinical practice varies substantially throughout the world. To consider the evidence for best practice to formulate management guidelines and to consider innovative therapies The Lawson Wilkins Pediatric Endocrine Society (LWPES) and The European Society for Pediatric Endocrinology (ESPE) convened a meeting in Gloucester MA March 14-17 2002. The 40 participating physicians psychologists scientists and surgeons from 12 countries on 4 continents agreed with the following consensus statement; this statement is concerned exclusively with CAH caused by 21-hydroxylase deficiency and does not address the other rarer forms of CAH. (excerpt)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
